Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Apellis Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Keli Walbert to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.